Bioprocess Online Live, Nov. 17, explores the current and future state of predictive control in biopharmaceutical manufacturing.

Register for free.

Sign up today: event.on24.com/wcc/r/5512381/…

Clonal cell line selection can take weeks (or longer), and that's why people like Susan Sharfstein, Ph.D., are devising ways to accelerate the process.

Watch the full interview with Sharfstein at Bioprocess Online or wherever you get your podcasts:
bioprocessonline.com/doc/streamlini…

Distance makes a quantifiable difference that POC manufacturing can solve, writes Boro Dropulić. For people in poverty living 50 miles-plus from academic medical centers, "each additional 10 miles lowers their likelihood of getting CAR-T therapy by 6%."

Futuristic vision or imminent reality? On Nov. 17, panelists from Sanofi, Octapharma, and PQE Group will discuss what it takes to move from automation to predictive control — and how soon we might see truly autonomous manufacturing.

Register for free: event.on24.com/wcc/r/5512381/…

War in the Gulf, tariffs up to 100%, and attacks on clinical trial data have a direct effect on most analytical disciplines but to varying degrees. Here's how one analyst describes the impact of global disruption on analytics.

Bridging the divide between the promises of AI and the current realities of biomanufacturing is critical to achieve the next generation of biopharma production.

See what James Colley, Ph.D., a senior director of BioPhorum, has to say about it:

bioprocessonline.com/doc/on-the-gro…

Will Olughu, Ph.D., came on the "Better Biopharma" podcast to discuss process modeling and AI applications in biopharma manufacturing. He explains what digital twins are (and aren't) and the challenge of implementation in GMP environments.

Listen here:

bioprocessonline.com/doc/implementi…

Tonix Pharmaceuticals' chief technical officer appeared on the "Better Biopharma" podcast to talk about the planning and construction of its purpose-built vaccine manufacturing facility.

Check out the full interview wherever you get your podcasts!

bioprocessonline.com/doc/building-a…

"AI systems built on broken architecture just fail faster and more expensively," said Martin Kockx, a principal manufacturing systems engineer at Vertex. Bioprocess Online caught up with him after his presentation at BPI.

See the full interview here: bioprocessonline.com/doc/contextual…

On #BusinessOfBiotech #podcast, @AkariTX's @RachelleJ7k discusses the redeeming qualities of #tick saliva and how her company is putting it to work to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy.

bioprocessonline.com/doc/tick-deriv…

On #BusinessOfBiotech #podcast, @AkariTX's @RachelleJ7k discusses the redeeming qualities of #tick saliva and how her company is putting it to work to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy.

bioprocessonline.com/doc/tick-deriv…

@ElicioTx’s novel Amphiphile Technology Platform directly engages the lymphatic system in the deployment and delivery of therapeutic payloads. #BusinessOfBiotech caught up with CSO Peter DeMuth to learn how the platform works. In partnership with @Cytiva.

bioprocessonline.com/doc/leveraging…

On #BusinessOfBiotech #podcast, @AkariTX's @RachelleJ7k discusses the redeeming qualities of #tick saliva and how her company is putting it to work to treat rare but deadly severe hematopoietic stem cell transplant-related thrombotic microangiopathy.

bioprocessonline.com/doc/tick-deriv…

@ElicioTx’s novel Amphiphile Technology Platform directly engages the lymphatic system in the deployment and delivery of therapeutic payloads. #BusinessOfBiotech caught up with CSO Peter DeMuth to learn how the platform works. In partnership with @Cytiva.

bioprocessonline.com/doc/leveraging…

Check out #BioprocessOnlineLive for a discussion on the application of process analytical technologies in biopharma manufacturing featuring Paul Testa, @KyowaKirin_US, @PharmatechA, and our own Matthew Pillar.

Supported by @SartoriusGlobal.

bioprocessonline.com/doc/biopharma-…

@ElicioTx’s novel Amphiphile Technology Platform directly engages the lymphatic system in the deployment and delivery of therapeutic payloads. #BusinessOfBiotech caught up with CSO Peter DeMuth to learn how the platform works. In partnership with @Cytiva.

bioprocessonline.com/doc/leveraging…

#BusinessOfBiotech #podcast is brought to you by @BioProcessOL in partnership with @Cytiva. Check out this week’s episode featuring @abbvie VP of Oncology Discovery, Steve Davidsen.

#oncology #drugdiscovery #computationalbiology

bioprocessonline.com/doc/oncology-d…

Available On-Demand - a discussion on the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations. Supported by Precision NanoSystems.

bioprocessonline.com/doc/lnps-beyon…

Check out #BioprocessOnlineLive for a discussion on the application of process analytical technologies in biopharma manufacturing featuring Paul Testa, @KyowaKirin_US, @PharmatechA, and our own Matthew Pillar.

Supported by @SartoriusGlobal.

bioprocessonline.com/doc/biopharma-…

@Obsidian_Tx's Paul Wotton takes #BusinessOfBiotech #podcast listeners behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called #OBX115.

bioprocessonline.com/doc/ind-for-ti…

Here's the story of BioStem Technologies (OTC: BSEM), its young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue.

bioprocessonline.com/doc/regenerati…

#BusinessOfBiotech #podcast is brought to you by @BioProcessOL in partnership with @Cytiva. Check out this week’s episode featuring @abbvie VP of Oncology Discovery, Steve Davidsen.

#oncology #drugdiscovery #computationalbiology

bioprocessonline.com/doc/oncology-d…

Available On-Demand - a discussion on the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations. Supported by Precision NanoSystems.

bioprocessonline.com/doc/lnps-beyon…

While the “rollout” of harmonized global regulatory requirements might be happening at a snail’s pace, progress is being made and the ICH remains the driver. #BioprocessOnlineLive

bioprocessonline.com/doc/where-is-g…

Check out #BioprocessOnlineLive for a discussion on the application of process analytical technologies in biopharma manufacturing featuring Paul Testa, @KyowaKirin_US, @PharmatechA, and our own Matthew Pillar.

Supported by @SartoriusGlobal.

bioprocessonline.com/doc/biopharma-…

During our recent #BioprocessOnlineLive event, many audience members had questions about what to expect in terms of differing expectations from various global regulatory agencies. In this segment of the discussion, two experts answer those questions.

@Obsidian_Tx's Paul Wotton takes #BusinessOfBiotech #podcast listeners behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called #OBX115.

bioprocessonline.com/doc/ind-for-ti…

Here's the story of @BSEM_Tech founders, Jason Matuszewski and Andrew Van Vurst, and how they reached commercial status in short order with a portfolio of proprietary regenerative #woundcare products developed from perinatal tissue.

#BusinessOfBiotech

bioprocessonline.com/doc/regenerati…

When it comes to all the moving parts of the reciprocal relationship between CMC and regulatory disciplines, do outsourcing partners help or hinder the complexity?

bioprocessonline.com/doc/cdmo-s-rol…

CMC decisions shouldn’t happen in a vacuum. Their regulatory implications certainly don’t. Who should be involved on cross-functional teams that influence CMC and regulatory dynamics?

bioprocessonline.com/doc/importance…

Here's the story of BioStem Technologies (OTC: BSEM), its young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue.

bioprocessonline.com/doc/regenerati…

#BusinessOfBiotech #podcast is brought to you by @BioProcessOL in partnership with @Cytiva. Check out this week’s episode featuring @abbvie VP of Oncology Discovery, Steve Davidsen.

#oncology #drugdiscovery #computationalbiology

bioprocessonline.com/doc/oncology-d…

In this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell and @AliraHealth's Steven Chamow discuss when comparability assessments are truly necessitated.

bioprocessonline.com/doc/comparabil…

Available On-Demand - a discussion on the scientific-, development-, and business-related advancements that will enable the RNA therapeutics industry to meet the needs of a broader array of patient populations. Supported by Precision NanoSystems.

bioprocessonline.com/doc/lnps-beyon…

In this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell, CEO of InScope Coaching & Consulting and Alira Health Senior VP of CMC Steven Chamow cover the highlights.

bioprocessonline.com/doc/which-regu…

What specific biopharma CMC changes invite regulatory scrutiny? Pretty much all of them. In this segment of the #BioprocessOnlineLive! event Regulatory Harmonization Meets CMC Realities, our panel discusses where many biopharma leaders get tripped up.

bioprocessonline.com/doc/cmc-change…

What specific biopharma CMC changes invite regulatory scrutiny? Pretty much all of them. In this segment of the #BioprocessOnlineLive! event Regulatory Harmonization Meets CMC Realities, our panel discusses where many biopharma leaders get tripped up.

bioprocessonline.com/doc/cmc-change…

During the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell and Steven Chamow took plenty of audience questions. In this segment they answer questions about ICH Q12.

bioprocessonline.com/doc/q-a-on-ich…

While the “rollout” of harmonized global regulatory requirements might be happening at a snail’s pace, progress is being made and the ICH remains the driver. #BioprocessOnlineLive

bioprocessonline.com/doc/where-is-g…

Now available on demand, #BioprocessOnlineLive tackles the hard questions around navigating international regulatory requirements, the work being done to streamline efforts, and how CMC leaders can best manage the ever-changing regulatory landscape.

bioprocessonline.com/doc/regulatory…

Why is taking the most stringent regulatory path forward a sound strategy in a multijurisdictional global filing effort? Find out in this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities.

bioprocessonline.com/doc/taking-the…

During our recent #BioprocessOnlineLive event, many audience members had questions about what to expect in terms of differing expectations from various global regulatory agencies. In this segment of the discussion, two experts answer those questions.

Here's the story of @BSEM_Tech founders, Jason Matuszewski and Andrew Van Vurst, and how they reached commercial status in short order with a portfolio of proprietary regenerative #woundcare products developed from perinatal tissue.

#BusinessOfBiotech

bioprocessonline.com/doc/regenerati…

@Obsidian_Tx's Paul Wotton takes #BusinessOfBiotech #podcast listeners behind the scenes to reveal what precipitated the FDA's clearance of its IND application for a novel, engineered tumor-infiltrating lymphocyte therapy called #OBX115.

bioprocessonline.com/doc/ind-for-ti…

When it comes to all the moving parts of the reciprocal relationship between CMC and regulatory disciplines, do outsourcing partners help or hinder the complexity?

bioprocessonline.com/doc/cdmo-s-rol…

CMC decisions shouldn’t happen in a vacuum. Their regulatory implications certainly don’t. Who should be involved on cross-functional teams that influence CMC and regulatory dynamics?

bioprocessonline.com/doc/importance…

Here's the story of BioStem Technologies (OTC: BSEM), its young founders, and how they reached commercial status in short order with a portfolio of proprietary regenerative wound care products developed from perinatal tissue.

bioprocessonline.com/doc/regenerati…

In this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell and @AliraHealth's Steven Chamow discuss when comparability assessments are truly necessitated.

bioprocessonline.com/doc/comparabil…

On #BusinessOfBiotech #podcast, @io_biotech CEO @ZoccaMai joins host @mattpillar to discuss the details of how the company’s lead immune-oncology candidate contrasts from previous attempts (think Merck c. 2018) targeting #IDO. In partnership with @Cytiva.

bioprocessonline.com/doc/ido-target…

During the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell and Steven Chamow took plenty of audience questions. In this segment they answer questions about ICH Q12.

bioprocessonline.com/doc/q-a-on-ich…

What specific biopharma CMC changes invite regulatory scrutiny? Pretty much all of them. In this segment of the #BioprocessOnlineLive! event Regulatory Harmonization Meets CMC Realities, our panel discusses where many biopharma leaders get tripped up.

bioprocessonline.com/doc/cmc-change…

In this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities, Stefanie Pluschkell, CEO of InScope Coaching & Consulting and Alira Health Senior VP of CMC Steven Chamow cover the highlights.

bioprocessonline.com/doc/which-regu…

While the “rollout” of harmonized global regulatory requirements might be happening at a snail’s pace, progress is being made and the ICH remains the driver. #BioprocessOnlineLive

bioprocessonline.com/doc/where-is-g…

During our recent #BioprocessOnlineLive event, many audience members had questions about what to expect in terms of differing expectations from various global regulatory agencies. In this segment of the discussion, two experts answer those questions.

Here's the story of @BSEM_Tech founders, Jason Matuszewski and Andrew Van Vurst, and how they reached commercial status in short order with a portfolio of proprietary regenerative #woundcare products developed from perinatal tissue.

#BusinessOfBiotech

bioprocessonline.com/doc/regenerati…

Now available on demand, #BioprocessOnlineLive tackles the hard questions around navigating international regulatory requirements, the work being done to streamline efforts, and how CMC leaders can best manage the ever-changing regulatory landscape.

bioprocessonline.com/doc/regulatory…

Why is taking the most stringent regulatory path forward a sound strategy in a multijurisdictional global filing effort? Find out in this segment of the #BioprocessOnlineLive event Regulatory Harmonization Meets CMC Realities.

bioprocessonline.com/doc/taking-the…

CMC decisions shouldn’t happen in a vacuum. Their regulatory implications certainly don’t. Who should be involved on cross-functional teams that influence CMC and regulatory dynamics?

bioprocessonline.com/doc/importance…

When it comes to all the moving parts of the reciprocal relationship between CMC and regulatory disciplines, do outsourcing partners help or hinder the complexity?

bioprocessonline.com/doc/cdmo-s-rol…